| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 318.20 | 22.5% | 17.3% |
| Total Income | 318.69 | 22.2% | 16.2% |
| Expenditure | 309.37 | 21.1% | 13.9% |
| PBT | 9.33 | 76.9% | 243.2% |
| Net Profit | 5.79 | 130.2% | 683.9% |
| OPM | 7.94% | 0.32pp | 1.58pp |
| NPM | 1.82% | 0.86pp | 1.55pp |
| EPS | 1.72 | 129.3% | 681.8% |
Record Revenue, Margin Gains—but Mahad Keeps the Verdict at Hold
Oriental Aromatics delivered its highest-ever quarterly revenue (₹318 Cr, +17% YoY) and expanded EBITDA margins 158 bps, yet guided steady-state growth of 10–12%—not higher. The call explains why: Mahad facility losses will drag profitability for 2–3 more quarters.
₹318.2 Cr
+17.3% YoY, +22.5% QoQ
₹5.8 Cr
1.8% margin; +128% YoY Q2-on-Q2
7.9%
+158 bps YoY
8.6%
Gap to consolidated 7.8% = Mahad drag
Oriental Aromatics closed Q2 with its highest quarterly revenue on record. The numbers look sharp on the headline: ₹318 Cr revenue, EBITDA margin of 7.9%, and PAT climbing 128% year-on-year. But step past the poster and the story tightens. Management declined to raise full-year guidance—instead reaffirming 10–12% steady-state growth from the prior call's 10–15% range. On a call where headline PAT growth is 128%, that feels reserved. It's not caution for caution's sake. It's Mahad.
The PAT Quality Issue: Low Base, Mahad Anchor
H1 PAT grew 592% year-on-year (₹8.3 Cr vs ₹1.2 Cr), which sounds extraordinary. It's not. The prior-year H1 base was a rounding error—Q1 FY'27 itself was only ₹2.48 Cr. Even on a standalone quarterly view, Q2 PAT at 128% YoY growth is impressive but lap-sensitive; it's also lapped a ₹2.5 Cr prior-year Q2. Strip the accounting: consolidated EBITDA margin of 7.8% sits 80 basis points below the standalone Amberath–Baroda–Bareilly facilities, which clock 8.6%. The gap is Mahad, the specialty aroma ingredients facility at Mahad. It runs at 50–55% of installed capacity, loses money, and will continue to drag consolidated profitability for 2–3 more quarters until it reaches 75–80% utilization and EBITDA neutrality. That timeline is management's own, not market consensus.
Revenue, though, is genuinely strong. H1 revenue of ₹578 Cr is up 16.3% year-on-year—already ahead of the prior call's guided 10–15% range for the full year. Q2 pushed higher on Fragrance division momentum (Amberath: +20% sales QoQ), industrial customer allocations ramping from prior RFQ cycles, and operational efficiency. Cash profit expanded 32.7% QoQ to ₹13.58 Cr, a positive signal on working-capital discipline.
Highest-ever quarterly revenue ₹318.19 Cr; +17% YoY, +22% QoQ
Delivered ₹318.2 Cr, 17.3% YoY, 22.5% QoQ
Supported
Q2 EBITDA margin improved to 7.94%, +158 bps YoY
Delivered 7.9%; EBITDA ₹25.26 Cr vs ₹17.2 Cr prior year
Supported
H1 revenue ₹578 Cr, +16.3% YoY; EBITDA margin 7.8%
Matches; H1 EBITDA ₹45.07 Cr vs ₹35.31 Cr FY'26 (+27.6%)
Supported
Mahad production +51% QoQ, sales +74% QoQ; still sub-optimal at 50–55%
Confirmed; management reaffirmed 75–80% target in 2–3 quarters
Supported
Unilever technical & manufacturing partnership announced
Confirmed as MoU-stage. Scope (CDMO/CMO), timeline, capex unquantified
Supported (but unproven)
What Changed This Quarter
The Unilever announcement is the strategic milestone. Management confirmed a technical, strategic, and manufacturing arrangement with Unilever Industries Private Limited—described as early-stage, structured as a Memorandum of Understanding. CEO Parag Satoskar declined to quantify scope, capex, timeline, or revenue contribution, citing confidentiality and MoU stage. Parag offered that it 'could take a couple of years to shape' and is framed as a long-term opportunity, not a near-term revenue driver. Investors pressed on structure (CDMO, CMO, co-invest?); the company held the line on 'more information when formalized.' This is neither a deal-risk nor a deal-done—it's a strategic signal that the internalization thesis (backward integration into specialty aroma ingredients) is attracting large FMCG partners. Execution remains to be seen.
On Mahad itself, no change to prior guidance. The facility continues to ramp (Q2 sales +74% QoQ from a low base), but utilization remains at 50–55% vs the 75–80% breakeven target. Management reaffirmed the 2–3-quarter timeline but offered no drill-down on customer allocations or contingency plan if the ramp slips. This persistence of the drag—acknowledged by CFO Shyamal Bodani as 'continues to be a drag on consolidated profitability'—is the reason guidance remained anchored at 10–12% growth and a 10% EBITDA margin target, not raised.
The Bull-Bear Ledger
Revenue growth beats prior guidance; H1 at 16.3% vs prior 10–15% range
EBITDA margin expanded 158 bps YoY despite raw material inflation (alpha-pinene, terpenes)
Fragrance division momentum (+7% H1 YoY, +20% Q2 QoQ sales); internalization program strengthening
Cash profit strong; working capital management intact despite higher inventory (RM inflation)
PAT growth headline inflated by low prior-year base; H1 comp was ₹1.2 Cr
Mahad operating at loss; will drag consolidated profitability 2–3 more quarters
Consolidated EBITDA margin (7.8%) sits 80 bps below standalone (8.6%); gap is pure Mahad drag
Camphor division facing structural headwinds: Q2 sales -5% QoQ, -8% YoY due to alpha-pinene inflation and price sensitivity in pooja market
Unilever partnership remains MoU-stage; unquantified and multi-year away from commercial shape
Net debt-to-equity rose to 0.64 from 0.56; driven by higher inventory and Q-end receivables spike
Risks, Ranked by Holder Concern
Mahad profitability timeline slip
HighFacility loss-making at 50–55% utilization; target 75–80% in 2–3 quarters. If ramp delays, consolidated margin stays compressed 7–8% range instead of recovering to 10% target. Each quarter of delay is ₹1–1.5 Cr in embedded losses.
Raw material inflation may not fully pass through
HighAlpha-pinene (Camphor feedstock), terpenes, petrochemicals remain elevated. Pooja market and commodity Camphor segment have zero pricing power; Q2 Camphor sales down 8% YoY despite cost inflation. Competitive intensity and customer pressure may cap margin recovery.
Unilever execution risk
MediumPartnership at MoU stage; scope and capex unquantified. If formalization stalls or scope shrinks, the strategic rationale (backward-integrated ingredients supply to FMCG anchor) becomes speculative. Currently priced in as 'long-term opportunity,' but credibility hangs on commercial progress.
Camphor market structural overcapacity
MediumDomestic Camphor market faces structural overcapacity and Chinese import competition. Bareilly facility is a mature cash-generator but a low-growth, low-margin anchor. No path to premium pricing unless entire industry consolidates or global alpha-pinene costs normalize.
Working capital deterioration under RM inflation
MediumNet debt-to-equity rose to 0.64 from 0.56 in one quarter. If raw material costs remain elevated and inventory buildup persists, debt could rise further, constraining capex flexibility and financial headroom for Mahad ramp investments.
How the Street Is Reading It
The market's response was cool. On day 1 (result announced Nov 4, 2026, pre-close ₹564.7), the stock fell 2.6%, suggesting the street discounted the headline beat. Current price of ₹497 (as of Nov 6) sits well below the stock's key moving averages: SMA20 (₹574), SMA50 (₹537)—both crossed downward. Relative to the 52-week range of ₹228–₹639, the stock is in the lower third. Most striking: it remains down 54.82% from its all-time high of ₹1,100, a structural reset from prior euphoria. RSI of 38.5 signals oversold but not capitulation.
Ownership remains heavily promoter-locked at 74.17% (unchanged across recent quarters). FII holding is negligible (0.02% as of Q1 FY'27, up just 2 basis points). DII presence is nil. The lack of institutional ownership—despite record revenue—suggests the street is waiting for two things: (1) Mahad to prove it can ramp to breakeven on schedule, and (2) Unilever partnership to crystallize into concrete commercial terms. The stock's posture—below moving averages, light institutional flow, heavy promoter anchor—is characteristic of a company in transition: operationally improving, but profitability visibility impaired by one major facility drag and one unproven strategic partnership.
The Debate
What to Watch Next
1 · Mahad utilization progression in Q3
Watch for utilization moving from 50–55% toward 60%+ and gross margin turning positive. If utilization is still sub-55% by Q3, the 75–80% target in '2–3 quarters' is slipping. This is the biggest profitability lever.
2 · Unilever partnership structure & capex commitment
The next earnings call or investor update should detail scope (CDMO, CMO, equity stake?), initial capex, and timeline to first commercial allocation. Any delay in formalization or capex reduction signals strategic pivot, not commitment.
3 · Raw material normalization & Camphor volume recovery
Camphor sales are down 8% YoY due to alpha-pinene inflation and pooja market price resistance. Track whether global alpha-pinene prices ease in H2 and whether Camphor volume rebounds. If RM inflation persists, margin recovery is further deferred.
Oriental Aromatics delivered a record revenue quarter, expanded margins, and beat prior guidance—operationally it's a solid quarter. But the company held guidance steady rather than raise it, the reason being Mahad: a facility that operates at a loss and will continue to drag consolidated profitability for 2–3 quarters as it ramps to breakeven utilization. PAT growth looks exceptional on the headline but rests on a low prior-year base; organic run-rate is much steadier. Unilever is a strategic signal but unquantified and years away from revenue shape.
This is steady execution, not a step-change. The company is worth owning on completion of Mahad's ramp-up and Unilever partnership formalization—likely 3–4 quarters ahead. For now, Hold. The number to track from here is Q3 Mahad utilization: if it's moving toward 60%+, the inflection case stays intact. If it stalls below 55%, Mahad becomes a structural drag, not a temporary one.
Record Q2 revenue, margin expansion offset by Mahad drag
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
H1 beat prior 10–15% guidance (16.3% delivered). Mahad target unchanged (75–80% utilization); reaffirmed, not withdrawn.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q2 revenue and margin beat delivery, but PAT growth is flattered by a low prior base. Mahad underutilization will drag profitability for 2–3 more quarters. Unilever partnership is a positive structural signal, but unquantified and early-stage. Guidance maintained (10–12% growth, 10% EBITDA margin target), not raised. Profitability margin still compressed at 1.8% NPM. Warrant a Hold pending Mahad's inflection and Unilever's commercial shape.
₹318.2 Cr
Revenue · +17.3% YoY₹5.8 Cr
Reported PAT · +683.9% YoYExpanding
Margins · vs guidance: MixedDid the claims hold up?
Highest-ever quarterly revenue ₹318.19 Cr, 17% YoY, 22% QoQ
METDelivered ₹318.2 Cr, 17.3% YoY, 22.5% QoQ—matches exactly
Q2 EBITDA margin improved to 7.94%, +32 bps QoQ, +158 bps YoY
METDelivered OPM 7.9%, reflecting 158 bps YoY expansion (Q2 ₹25.26 Cr vs ₹17.2 Cr prior year)
PAT grew substantially; Q2 PAT ₹5.70 Cr (1.82% margin)
MixedQ2 PAT grew ~128% YoY (₹5.70 Cr vs ₹2.5 Cr); H1 PAT grew ~592% (₹8.3 Cr vs ₹1.2 Cr). Delivered states 683.9% YoY, which appears to conflate H1 growth or includes rounding variance.
H1 revenue ₹578 Cr, up 16.3% YoY; EBITDA margin improved to 7.8%
METMatches; H1 EBITDA ₹45.07 Cr vs ₹35.31 Cr FY'26, +27.6% YoY; standalone margin 8.6%
Mahad production +51% QoQ, sales +74% QoQ; still sub-optimal at 50–55% utilization
METMahad volumes ramping; management reaffirmed 75–80% utilization target for EBITDA neutrality in 2–3 quarters. Acknowledged 'continues to be a drag on consolidated profitability.'
Announced Unilever partnership; technical, strategic, and manufacturing arrangement
METConfirmed; structured as MoU. Management declined to quantify scope, timeline, or investment. Described as long-term, early-stage.
Earnings quality
What changed since the last call
Unilever technical arrangement announced
NewAnnounced in Q2 as strategic & manufacturing partnership. Structure unconfirmed (CDMO/CMO/co-invest). MoU stage; Parag said 'could take couple of years to shape.'
Mahad utilization timeline reiterated
NeutralPrior call targeted 75–80% utilization for EBITDA neutrality; this call reaffirmed target in '2–3 quarters.' No change in trajectory or ambition, but no acceleration signaled.
Revenue growth guidance narrowed verbally
NeutralPrior: 'FY27 10–15% growth.' This call: 'steady growth 10–12%' (per Parag, discussing long-term Unilever context). H1 delivery at 16.3% already exceeds both ranges—no downside signal.
EBITDA margin target articulated
NeutralParag: 'targeting 10% first, then go forward.' Implies 2–3 quarters to reach 10%, consistent with Mahad ramp-up timeline. Not a formal guided uplift, but reaffirms direction.
The Q&A
Moderate Q&A pressure on Unilever scope, Mahad timeline, and capex plans. Management deflected Unilever details (Saket Saurav's CDMO/CMO question)—Parag said confidentiality and MoU stage. Sanjay Nandy asked for forward growth scenario; Parag gave vague '10–12% CAGR' without Unilever upside quantified. Rohan Jain's efficiency program question was answered but without specifics. Overall, analysts accepted cautious tone but sought clearer visibility on Unilever and Mahad mechanics.
Unilever partnership structure — Saket Saurav, Sagari Capital
DodgedNature of arrangement work-in-progress. More details when formalized. Encouraging arrangement. Translations to numbers once clarity achieved. Early stage; MoU.
Mahad EBITDA break-even — Saket Saurav, Sagari Capital
DodgedParag redirected: 'let kind of have more questions first.' Did not directly answer.
Long-term growth with Unilever — Sanjay Nandy, AMPL
PartialAlways looking at steady growth, 10–12% CAGR in profitability and sales. Broader opportunities will be shared if available. Will translate into numbers.
EBITDA margin target trajectory — Sanjay Nandy, AMPL
Answered10% is a target being pursued. Multiple challenges (RM inflation, capacity, R&D investments) impacting margin. Operational efficiency ongoing. First factors being addressed.
Efficiency program margin uplift — Rohan Jain, (Individual)
AnsweredOperational efficiency program has multiple elements. Cannot give exact %. Objective is to reach 10% EBITDA. Programs are product-driven, focused on competitiveness in global space.
RFQ-to-commercial conversion — Rohan Jain, (Individual)
AnsweredYes. RFQs filled in June became operational from July, hitting numbers in Q2 (this quarter). Ongoing allocations scaling.
Net debt increase — Rakesh Kumar, (Individual)
AnsweredHigher inventory levels due to raw material cost inflation. Increase in receivables—sales occurred late in quarter, accumulated. Higher working capital cost requirement.
Fragrance revenue mix and H2 order pipeline — Rakesh Kumar, (Individual)
AnsweredFragrance division showing encouraging growth over past few years. Uniform growth across FMCG clients and global customers. Internalization program (backward integration into aroma ingredients) is strong value driver. Ratio maintained 1/3rd:1/3rd:1/3rd (three divisions).
Camphor festive demand and competition — Sagar Shah, (Individual)
AnsweredQ2 Camphor volumes lower (down 8% YoY) due to alpha-pinene price elevation (global phenomenon). Market very price-sensitive in pooja segment. Camphor prices higher globally; power prices high. Pass-through with customers difficult in price-sensitive pooja market. Current Camphor powder ground prices are not actual pass-through; competitive dynamics restrict hikes.
Mahad production capacity utilization and trajectory — Sagar Shah, (Individual)
AnsweredCurrently 50–55% utilization at Mahad. Target to reach 75–80% optimum in 2–3 quarters. Ongoing allocation conversations with existing and new customers; RFQ allocations slowly scaling. Objective: achieve optimum utilization in next 2–3 quarters, then look at ability to increase pricing at customer level.
Full-year PAT guidance — Pradeep, (Individual)
AnsweredYes, correct.
Guidance
FY27 revenue growth 10–12% steady-state (reaffirmed from prior call's 10–15% range)
MediumH1 delivered 16.3%, already exceeding upper bound. Management softened forward view to 10–12% 'steady growth,' suggesting near-term saturation post-Unilever ramp-up. Long-term ambition contingent on Mahad inflection and Unilever commercial shape.
EBITDA margin target 10% (no timeline specified beyond 'first reach 10%, then go forward')
MediumCurrent consolidated 7.9% (Q2), 7.8% (H1). Standalone 8.6%. Gap due to Mahad losses (~50–55% utilization). Parag said operational efficiency and Mahad ramp will drive toward 10% over coming quarters (implied 2–3 quarters in line with Mahad timeline).
No formal capex guidance provided. In 'consolidation phase'—focus on utilization of existing assets.
LowParag said company is in 'consolidation phase,' not substantial capex planned. Mahad infrastructure already built for future expansion; focus is filling current capacity. R&D and efficiency investments ongoing but unquantified.
Risks the call surfaced
Mahad profitability drag
HighMahad facility operating at 50–55% utilization vs 75–80% breakeven target. Currently loss-making, dragging consolidated EBITDA margin (standalone 8.6% vs consolidated 7.8%). Ramp timeline uncertain; management says 2–3 quarters but this may slip.
Raw material cost inflation
HighAlpha-pinene (Camphor raw material), terpenes, petrochemical-derived materials remain elevated and volatile. Competitive market and price-sensitive customers (e.g., pooja segment) limit pass-through ability. Camphor Q2 sales down 5–8% YoY due to price elasticity.
Camphor market structure overcapacity
MediumDomestic Camphor market characterized by structural overcapacity and competitive pricing. Large local players and import competition (Chinese imports) restrict price increases even as costs rise. Customer concentration in price-sensitive B2C (pooja, ritual) segment.
Unilever partnership execution risk
MediumAnnounced Unilever technical/strategic/manufacturing arrangement remains at MoU stage. Scope (CDMO, CMO, co-invest), timeline, capex, and revenue contribution unquantified. Management flagged uncertainty; could take 'couple of years' to shape.
Geopolitical and currency volatility
MediumGeopolitical uncertainty, currency movements, and volatility in petrochemical feedstocks (globally sourced) impact procurement and manufacturing costs. Ongoing macro headwinds noted by management but not quantified.
Management
Score 6/10. Cautious and selective. Transparent on operational metrics and quarterly performance; evasive on Unilever scope and Mahad timelines. CFO provided detailed financial breakdowns; CEO articulated strategy but with hedges. No NDA-shields claimed. Met H1 revenue guidance (16.3% vs prior 10–15% range). Mahad ramp-up in progress (50–55% utilization, targeting 75–80% in 2–3 quarters); timeline not yet breached but unproven. PAT growth is 128% YoY in Q2 (good) but masks Mahad drag and low prior base (H1 base was ₹1.2 Cr).
1 · Q3–Q4 FY'27
Mahad reaching 75–80% capacity utilization; shift from loss to EBITDA neutral
2 · H2 FY'27
Unilever partnership formal structure and initial commercial allocations defined
3 · FY'28
Alpha-pinene price normalization; Camphor volume recovery if global supply eases
Warrant a Hold pending Mahad's inflection and Unilever's commercial shape.